The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression
Open accessAbstract
IMPORTANCE: It remains unclear whether vitamin D insufficiency, which is common in individuals with multiple sclerosis (MS), has an adverse effect on MS outcomes. OBJECTIVES: To determine whether serum concentrations of 25-hydroxyvitamin D (25[OH]D), a marker of vitamin D status, predict disease activity and prognosis in patients with a first event suggestive of MS (clinically isolated syndrome). DESIGN, SETTING, AND PARTICIPANTS: The Betaferon/Betaseron in Newly Emerging multiple sclerosis For Initial Treatment study was a randomized trial originally designed to evaluate the impact of early vs delayed interferon beta-1b treatment in patients with clinically isolated syndrome. Serum 25(OH)D concentrations were measured at baseline and 6, 12, and 24 months. A total of 465 of the 468 patients randomized had at least 1 25(OH)D measurement, and 334 patients had them at both the 6- and 12-month (seasonally asynchronous) measurements. Patients were followed up for 5 years clinically and by magnetic resonance imaging. MAIN OUTCOMES AND MEASURES: New active lesions, increased T2 lesion volume, and brain volume on magnetic resonance imaging, as well as MS relapses and disability (Expanded Disability Status Scale score). RESULTS: Higher 25(OH)D levels predicted reduced MS activity and a slower rate of progression. A 50-nmol/L (20-ng/mL) increment in average serum 25(OH)D levels within the first 12 months predicted a 57% lower rate of new active lesions (P < .001), 57% lower relapse rate (P = .03), 25% lower yearly increase in T2 lesion volume (P < .001), and 0.41% lower yearly loss in brain volume (P = .07) from months 12 to 60. Similar associations were found between 25(OH)D measured up to 12 months and MS activity or progression from months 24 to 60. In analyses using dichotomous 25(OH)D levels, values greater than or equal to 50 nmol/L (20 ng/mL) at up to 12 months predicted lower disability (Expanded Disability Status Scale score, -0.17; P = .004) during the subsequent 4 years. CONCLUSIONS AND RELEVANCE: Among patients with MS mainly treated with interferon beta-1b, low 25(OH)D levels early in the disease course are a strong risk factor for long-term MS activity and progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Self-citationAccurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis
Smith, S. M., Zhang, Y., Jenkinson, M., Chen, J., Matthews, P. M., Federico, A., & De Stefano, N. (2002) · NeuroImage · doi:10.1006/nimg.2002.1040 · Cited by 2,013
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., & Ascherio, A. (2006) · JAMA · doi:10.1001/jama.296.23.2832 · Cited by 1,897
Self-citationMultiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
Common genetic determinants of vitamin D insufficiency: a genome-wide association study
Wang, T. J., Zhang, F., Richards, J. B., Kestenbaum, B., van Meurs, J. B., Berry, D., Kiel, D. P., Streeten, E. A., Ohlsson, C., Koller, D. L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60588-0 · Cited by 1,540
Vitamin D intake and incidence of multiple sclerosis
Munger, K. L., Zhang, S. M., O’Reilly, E., Hernán, M. A., Olek, M. J., Willett, W. C., & Ascherio, A. (2004) · Neurology · doi:10.1212/01.wnl.0000101723.79681.38 · Cited by 1,093
Self-citationFisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
Self-citationGenome-wide association study of circulating vitamin D levels
Ahn, J., Yu, K., Stolzenberg-Solomon, R., Simon, K. C., McCullough, M. L., Gallicchio, L., Jacobs, E. J., Ascherio, A., Helzlsouer, K., Jacobs, K. B., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq155 · Cited by 810
Self-citationLooker, A. C., Dawson-Hughes, B., Calvo, M. S., Gunter, E. W., & Sahyoun, N. R. (2002) · Bone · doi:10.1016/s8756-3282(02)00692-0 · Cited by 803
Vitamin D: its role and uses in immunology 1
Deluca, H. F., & Cantorna, M. T. (2001) · The FASEB Journal · doi:10.1096/fj.01-0433rev · Cited by 784
Hyppönen, E., & Power, C. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.3.860 · Cited by 756 · cited 2×
“25(OH)D, median (range), nmol/L 31 (19-36) 40 (36-45) 48 (45-52) 56 (52-61) 69 (61-98) 39 (19-50) 60 (50-98)”
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 681
Self-citationKappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.003 · Cited by 549
Self-citationKappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H.-P., Miller, D. H., Montalbán, X., Barkhof, F., Radü, E.-W., Bauer, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61194-5 · Cited by 502
Self-citationHigher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis
Simpson, S., Taylor, B., Blizzard, L., Ponsonby, A., Pittas, F., Tremlett, H., Dwyer, T., Gies, P., & van der Mei, I. (2010) · Annals of Neurology · doi:10.1002/ana.22043 · Cited by 457
Kappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H.-P., Miller, D. H., Montalbán, X., Barkhof, F., Radü, E.-W., Metzig, C., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70237-6 · Cited by 369
Self-citationVitamin D status is associated with relapse rate in pediatric‐onset multiple sclerosis
Mowry, E. M., Krupp, L. B., Milazzo, M., Chabas, D., Strober, J. B., Belman, A. L., McDonald, J. C., Oksenberg, J. R., Bacchetti, P., & Waubant, E. (2010) · Annals of Neurology · doi:10.1002/ana.21972 · Cited by 329
Banwell, B., Bar-Or, A., Arnold, D. L., Sadovnick, D., Narayanan, S., McGowan, M., O'Mahony, J., Magalhaes, S., Hanwell, H., Vieth, R., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70045-x · Cited by 319
The initiation and prevention of multiple sclerosis
Ascherio, A., Munger, K. L., & Lünemann, J. D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.198 · Cited by 289
Self-citationBaseline MRI predicts future attacks and disability in clinically isolated syndromes
Tintoré, M., Rovira, A., Río, J., Nos, C., Grivé, E., Téllez, N., Pelayo, R., Comabella, M., Sastre-Garriga, J., & Montalban, X. (2006) · Neurology · doi:10.1212/01.wnl.0000237354.10144.ec · Cited by 282
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis
Mowry, E. M., Waubant, E., McCulloch, C. E., Okuda, D. T., Evangelista, A. A., Lincoln, R. R., Gourraud, P., Brenneman, D., Owen, M. C., Qualley, P., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23591 · Cited by 270
Soilu-Hänninen, M., Åivo, J., Lindström, B.-M., Elovaara, I., Sumelahti, M.-L., Färkkilä, M., Tienari, P., Atula, S., Sarasoja, T., Herrala, L., et al. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301876 · Cited by 269
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
Zivadinov, R., Reder, A. T., Filippi, M., Minagar, A., Stüve, O., Lassmann, H., Racke, M. K., Dwyer, M. G., Frohman, E. M., & Khan, O. (2008) · Neurology · doi:10.1212/01.wnl.0000316810.01120.05 · Cited by 260
Vitamin D3 Confers Protection from Autoimmune Encephalomyelitis Only in Female Mice
Spach, K. M., & Hayes, C. E. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.4119 · Cited by 250
Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis
Runia, T. F., Hop, W. C. J., de Rijke, Y. B., Buljevac, D., & Hintzen, R. Q. (2012) · Neurology · doi:10.1212/wnl.0b013e31825fdec7 · Cited by 229
Vitamin D as a protective factor in multiple sclerosis
Salzer, J., Hallmans, G., Nyström, M., Stenlund, H., Wadell, G., & Sundström, P. (2012) · Neurology · doi:10.1212/wnl.0b013e3182752ea8 · Cited by 228
Kampman, M. T., Steffensen, L. H., Mellgren, S. I., & Jørgensen, L. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458511434607 · Cited by 200
Becklund, B. R., Severson, K. S., Vang, S. V., & DeLuca, H. F. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001119107 · Cited by 199
Health‐related quality of life in multiple sclerosis: effects of natalizumab
Rudick, R. A., Miller, D., Hass, S., Hutchinson, M., Calabresi, P. A., Confavreux, C., Galetta, S. L., Giovannoni, G., Havrdova, E., Kappos, L., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21163 · Cited by 195
Self-citationA randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis
Stein, M. S., Liu, Y., Gray, O. M., Baker, J. E., Kolbe, S. C., Ditchfield, M. R., Egan, G. F., Mitchell, P. J., Harrison, L. C., Butzkueven, H., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182343274 · Cited by 185
Determinants of plasma 25-hydroxyvitamin D and development of prediction models in three US cohorts
Bertrand, K. A., Giovannucci, E. L., Liu, Y., Malspeis, S., Eliassen, A. H., Wu, K., Holmes, M. D., Laden, F., & Feskanich, D. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114511007409 · Cited by 147
Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes
Martinelli, V., Costa, G. D., Colombo, B., Libera, D. D., Rubinacci, A., Filippi, M., Furlan, R., & Comı, G. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513494959 · Cited by 138
Smolders, J., Hupperts, R., Barkhof, F., Grimaldi, L. M. E., Holmøy, T., Killestein, J., Rieckmann, P., Schluep, M., Vieth, R., Gottwald‐Hostalek, U., et al. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.04.013 · Cited by 116
Self-citationVitamin D and disease activity in multiple sclerosis before and during interferon-β treatment
Løken-Amsrud, K. I., Holmøy, T., Bakke, S. J., Beiske, A. G., Bjerve, K. S., Bjørnarå, B. T., Hovdal, H., Lilleås, F., Midgard, R., Pedersen, T., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31825fdf01 · Cited by 107
Lucas, R. M., & Ponsonby, A. (2006) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2006.02.019 · Cited by 81
Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis
Simon, K. C., Munger, K. L., Kraft, P. L., Hunter, D. J., Jager, P. L. D., & Ascherio, A. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6001-5 · Cited by 68
Self-citationVitamin D intake and incidence of multiple sclerosis
Ebers, G. C., Sadovnick, A. D., & Veith, R. (2004) · Neurology · doi:10.1212/wnl.63.5.939 · Cited by 59
Barkhof, F., Polman, C. H., Radue, E. W., Kappos, L., Freedman, M. S., Edan, G., Hartung, H., Miller, D. H., Montalbán, X., Poppe, P. A., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.9.1292 · Cited by 53
Self-citationAscherio, A., & Marrie, R. A. (2012) · Neurology · doi:10.1212/wnl.0b013e31825fe131 · Cited by 20
Self-citation
Cited by
Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30481-1 · Cited by 1,797
Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis
Olsson, T., Barcellos, L. F., & Alfredsson, L. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.187 · Cited by 1,185
ESPEN guideline clinical nutrition in neurology
Burgos, R., Bretón, I., Cereda, E., Desport, J. C., Dziewas, R., Genton, L., Gomes, F., Jésus, P., Leischker, A., Muscaritoli, M., et al. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.09.003 · Cited by 571
Long‐term evolution of multiple sclerosis disability in the treatment era
University of California, S. F. M. T., Cree, B. A. C., Gourraud, P., Oksenberg, J. R., Bevan, C., Crabtree‐Hartman, E., Gelfand, J. M., Goodin, D. S., Graves, J., Green, A. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24747 · Cited by 440
Vitamin D and Multiple Sclerosis: A Comprehensive Review
Sintzel, M. B., Rametta, M., & Reder, A. T. (2018) · Neurology and Therapy · doi:10.1007/s40120-017-0086-4 · Cited by 435
Metadata
- Authors
- Ascherio, A., Munger, K. L., White, R., Köchert, K., Simon, K. C., Polman, C. H., Freedman, M. S., Hartung, H.-P., Miller, D. H., Montalbán, X., Edan, G., Barkhof, F., Pleimes, D., Radü, E.-W., Sandbrink, R., Kappos, L., & Pohl, C.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2014-03-01
- Volume
- 71
- Issue
- 3
- Pages
- 306
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2109752085
- Cited by
- 516
- References
- 42
- FWCI
- 46.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.